Summary: A critical evaluation of the determination of acid phosphatase of prostatic origin with the Du Pont ACA is reported. The affinity of the enzyme towards certain substrates, and the specificity of sodium thymolphthalein monophosphate as a substrate for prostatic acid phosphatase were investigated. The validity of this method, which is supposed to be specific for prostatic phosphatase is, however, limited; clinical data showed that related human acid phosphatases interfere and decrease the specificity of the determination.
Introduction
It is claimed that the Du Pont Automatic Clinical Analyt . . , __ .
zer ACA 1 ) measures quantitatively the acid phosphatase Since the findings of Gutman et al (1) and Huggms & pf prostatic origin> and that the substrate used (sodium Hodges (2) that serum acid phosphatase (EC 3. 1. 3.2) thymolphthalein monophosphate) is more specific for activity is markedly increased in patients with prostatic ^ prostatic enzyme than other currently used substrates, carcinoma, determination of this enzyme activity has
With the introduction o f this instrument into our laborabeen widely used in the detection of prostatic cancer tory $ ft was therefore of i nter est to examine whether the and in monitoring the therapy of this disease (3) . me thod distinguishes between closely related, but differ-A number of procedures, involving different substrates, ent phosphatases, and to test whether the method gives buffers, or variations of other conditions such as inhibireliable results, tors (4) , have been used for the assay of prostatic acid phosphatase in serum. Despite these variations, any assay based on the measurement of catalytic activity is subject i ; £ L de Du Pont Nempurs and Co. (Inc.), Instruments to interference by phosphatases of non prostatic origin.
Products Division, Wilmington, Del 19898 USA. 2. Routinely the enzyme determinations were performed in sodium acetate (pH 5.5). Since the ACA method is an adaptation of the thymolphthalein monophosphate hydrolysis method in citrate buffer, we also performed the above assays in 0.1 mol/l sodium citrate.
Crude enzyme preparation of prostatic origin
Fresh, human prostatic tissue was the source of enzyme. After excission the gland was frozen and stored at -20 °C. All further procedures were carried out at + 4 °C. An extract of the prostatic tissue was prepared as follows, the frozen prostate gland was sliced into thin sections and these were added to 200 ml 0.1 mol/l sodium acetate (pH 5.5). The mixture was homogenized in a Waring Blendor (15.000 X g; 30 min) and the supernatant was decanted and used for further experiments.
Crude enzyme preparation of human erythrocytes
One half liter of fresh blood was centrifuged at 10000 g for 10 min at 4 °C. After removing the plasma and the leucocytes the residue was washed three times with cold physiological saline. The erythrocytes were hemolyzed with four volumes of 5 mmol/1 sodium acetate pH 5.5 containing 0.25 ml/1 Triton X-100. After standing for 15 min the solution was centrifuged (30000 g for 30 min at 4 °C). The supernatant was dialyzed against 1 mmol/1 sodium acetate (pH 5.5) for 24 hours at 4 °C followed by concentration against polyethylene glycol. From the concentrated dialyzed hemolysate (100 ml), 20 ml was applied to a DEAE sephadex A-50 column (50 X 0.5 cm). Hemoglobin was eluted from the column in the cold with 100 ml cold equilibration buffer, 1 mmol/1 sodium acetate (pH 5.5). Chromatography was continued with a linear gradient of sodium acetate (pH 5.5), followed by elution of the column with 1 mol/l NaCl. Fractions of 3 ml were collected, while the flow rate was 3 ml per hour. The fractions were assayed for acid phosphatase activity with p-nitrophenyl phosphate as the substrate. The enzymatically active fractions were pooled, concentrated and used for further experiments.
Acid phosphatase of the spleen
A crude preparation of human splenic tissue was prepared essentially as described for the prostatic preparation.
Results

Characterization of the prostatic enzyme preparation
With p-nitrophenyl phosphate as substrate, the phosphatase activity of the crude prostatic extract was inhibited 98% by 10 mmol/1 L-tartrate. This confirms the identity of the prostatic phosphatase, and is in agreement with other authors (4).
The enzyme was also inactivated by ferric ions, as already reported by other authors (7). Inhibition was 95%, 40% and 15% with 1.0,0.5 and 0.25 mmol/1 ferric chloride, respectively. The inhibition by Ζ,-tartrate was also studied over a range of substrate concentrations (10 mmol/1-10 μπιοΙ/1) yielding an inhibition constant KI = 35 μιηοΐ/ΐ. This value is in agreement with those obtained by Kilsheimer&Axelrod (8) .
Substrate specificity of the prostatic enzyme preparation
K m values for various substrates in acetate buffer were determined by zLineweaver-Burk plot (9) , and the results are summarized in table 1.
These values indicate that our prostatic enzyme preparation has a higher affinity for the substrate a-naphthyl phosphate than for sodium thymolphthalein monophosphate. Since the AC A method is an adaptation of the method of Roy et al (6) , who originally used citrate buffer, we repeated the K m determinations in this buffer. These results are also shown in table 1; again, the enzyme shows highest affinity for α-naphthylphosphate.
Interference by other acid phosphatases
The above results do not exclude the possibility that prostatic acid phosphatase is specific for sodium thymolphthalein monophosphate. We therefore isolated the acid phosphatase of human erythrocytes by DEAE Sephadex chromatography. Three separated and distinct peaks of acid phosphatase were obtained, as already described (10) . The three peaks were combined for further study. Erythrocytic acid phospHatase preparation (20 U/l by the α-naphthylphosphate method) was mixed with an equal volume of serum from a healthy woman containing negligible acid phosphatase as determined with the ACA. Acid phosphatase activity was then determined with the ACA. We repeated the experiment with an erythrocytic acid phosphatase preparation containing 5.0 U/l. The results in table 2 clearly show interference by erythrocytic acid phosphatase in the determination of prostatic acid phosphatase with the Du Pont ACA. Similar experiments with the splenic acid phosphatase also showed interference by this enzyme in the determination of prostatic acid phosphatase (table 2) . Thus, the determination of acid phosphatases of prostatic origin with the Du Pont ACA is influenced by other phosphatases.
To verify these findings, we determined acid phosphatase with the Du Pont ACA in 35 cancer patients (20 men, 15 women), including patients with multiple myeloma, various leukemias, various bone disorders,Hodgkin 's disease, thrombocytaemia, but not prostatic cancer.
Tab. 2. Experiments to investigate the specificity of the Du Pont ACA. To 1 ml serum of a healthy woman, with negligible acid phosphatase activity determined with the ACA, was added 1 ml of an erythrocytic acid phosphatase preparation containing 200 U/l determined with the a-naphthylphosphate method. In the mixture the activity was determined with the ACA, The experiment was repeated with addition of an erythrocytic acid phosphatase preparation containing 5.0 U/l. Above experiments were also performed with an acid phosphatase preparation from the spleen, at the same levels of addition. In 5 specimens the result was higher than the norm. One of the elevated samples (5.6 IU/1) was from a woman with adenocarcinoma with metastases.
Discussion
The high specificity of enyzmes, that is to say, the strict limitation of the action of each enzyme to one substrate or to a very small number of closely related substances is one of their most striking characteristics. Although the prostate is by far the richest source of acid phosphatase, this Enzyme is found in all cells that contain lysosomes. Therefore it is not surprising that increased acid phosphatase in serum has been found in a number of diseases other than prostatic carcinoma. Significant elevation of serum acid phosphatase has been observed in patients with Gaucher's disease,· myeloma, leukemia, thrombocytosis, osteogenic sarcoma and various bone disorders involving osteoclastic activity (11) . Differentiation of prostatic acid phosphatases from the enzymes derived from other tissues has received attention in various studies. In the study of Roy et al (6) it has been shown that thymolphthalein monophosphate is more specific than phenylphosphate, α-naphthylphosphate and p-nitrophenylphosphate for prostatic acid phosphatase, whereas a similar specificity for the enzyme from erythrocytes, liver, kidney, bone and platelets is lacking. In their clinical studies no falsely positive results were obtained with this substrate in the sera of non prostatic cancer patients. Their results were confirmed partly by Foti et al (12) who reported thymolphthalein monophosphate to be the most specific substrate for prostatic acid phosphatase. However, they reported 26% false positives from non prostatic cancer patients determined with their enzymatic assay, leaving undecided whether these above normal results also were obtained with the substrate sodium thymolphthalein monophosphate. Li et al (11) came to the conclusion that both α-naphthylphosphate and thymolphthalein monophosphate were good but not specific substrates for prostatic acid phosphatase.
In view of these reports, together with our knowledge of acid phosphatase (5, 13) , and the fact that we were interested in the quantitative measurement the acid phosphatase of prostatic origin, the ACA method was further investigated. We confirmed both the /,-tartrate (4) and ferric ion (7) inhibition of our prostatic enzyme.
In carrying out a specificity study it is usual to select a reference substrate, which is generally the most readily attacked biological substrate and to work out optimum conditions for this. Other possible substrates are then examined under the same conditions of pH, temperature and concentration. In our case we used the conditions of the ACA method, which are based on an adaptation of the method of Roy et al (6) . One can clearly conclude from the results of our kinetic experiments, that the affinity of acid phosphatase of prostatic origin is higher for -naphthylphosphate than for the substrate sodium thymolphthalein monophosphate. These results also indicate that the enzyme investigated here, acid phosphatase of prostatic origin, is not a very specific one because it is acting on several related substrates. Bearing this in mind, and the fact that the acid phosphatases from erythrocytes and spleen hydrolyse the substrate sodium thymolphthalein monophosphate (tab. 2), this picture of a method which quantitatively measures the acid phosphatase of prostatic origin becomes severely blurred. We can conclude that the method proposed by the manufacturers of the ACA is indeed an assay system for acid phosphatase of prostatic origin, but that it is subject to interference by other phosphatases and its value as a quantitative procedure for prostatic acid phosphatase is limited. This is supported by our clinical studies on the ACA. It is apparent from the acid phosphatase activities found in patients of non-prostatic origin, that the substrate is not completely specific for the prostatic form of the enzyme. We have no explanation for the discrepancy between the clinical findings of Roy et al (6) , who found no values above the norm in sera of non-prostatic cancer patients, and our results. We do not believe that it is a result of a minor modification in the adaptation of the thymolphthalein monophosphate method on the ACA; Li et al (11) also reported a patient with elevated acid phosphatase activity as determined with the sodium thymolphthalein monophosphate method.
From the literature it is already clear that the substrates used to measure serum acid phosphatase in prostatic cancer patients, including phenylphosphäte, p-nitrophenylphosphate, jS-glycerophosphate, phenolphthalein diphosphate and -naphthylphosphate, are not specific for acid phosphatase of prostatic origin; our results show that sodium thymolphthalein monophosphate is also hydrolyzed by various acid phosphatases.
